Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 2/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.30 |
| ▸ | LIPC | P11150 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19670516 | 0.93 | SCD (0.38) | SCDFGFR4DEGS1LPLLIPC | |
| SCHEMBL17618900 | 0.86 | SCD (0.34) | SCDFGFR4DEGS1 | |
| SCHEMBL19669073 | 0.83 | SCD (0.37) | SCDFGFR4DEGS1LPLLIPC | |
| SCHEMBL17618391 | 0.81 | SCD (0.41) | SCDDEGS1 | |
| SCHEMBL17618519 | 0.80 | SCD (0.43) | SCDDEGS1 | |
| SCHEMBL17618376 | 0.79 | GRM5 (0.39) | SCD | |
| SCHEMBL17618513 | 0.79 | HCRTR1 (0.42) | SCD | |
| SCHEMBL17618541 | 0.79 | SCD (0.38) | SCDFGFR4DEGS1LPLLIPC | |
| SCHEMBL17618499 | 0.79 | GRM5 (0.39) | SCD | |
| SCHEMBL17618590 | 0.78 | TRPV1 (0.36) | SCDFGFR4DEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | SCD 928/4885FGFR4 2275/4885DEGS1 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.